Clinical Trial Detail

NCT ID NCT02296112
Title Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

melanoma

Therapies

Trametinib

Age Groups: senior adult

Additional content available in CKB BOOST